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Abstract
Background: ATP-binding cassette transporter A1 (ABCA1) mediates the lipidation of exchangeable
apolipoproteins, the rate-limiting step in the formation of high density lipoproteins (HDL). We previously
demonstrated that HDL oxidized ex vivo by peroxidase-generated tyrosyl radical (tyrosylated HDL, tyrHDL) increases
the availability of cellular cholesterol for efflux and reduces the development of atherosclerosis when administered
to apolipoprotein E-deficient mice as compared to treatment with control HDL.
Results: In the current study we determined that tyrHDL requires functional ABCA1 for this enhanced activity. Like
lipid-free apolipoprotein A-I (apoA-I), tyrHDL increases total and cell surface ABCA1, inhibits calpain-dependent and
-independent proteolysis of ABCA1, and can be bound by cell surface ABCA1 in human skin fibroblasts.
Additionally, tyrHDL apoproteins are susceptible to digestion by enteropeptidase like lipid-free apoA-I, but unlike
lipid-bound apoA-I on HDL, which is resistant to proteolysis.
Conclusions: These results provide the first evidence that lipid-bound apolipoproteins on the surface of spherical
HDL particles can behave like lipid-free apoA-I to increase ABCA1 protein levels and activity.
Background
High density lipoprotein cholesterol (HDL-C) levels in
human plasma correlate generally with protection
against coronary heart disease, an effect believed to be
due to multiple protective actions of HDL including sti-
mulating the removal of excess cholesterol from cells
and reducing inflammation in the artery wall [1]. The
initial formation of HDL particles requires the mem-
brane lipid transporter ATP-binding cassette transporter
A1 (ABCA1) to mediate delivery of cellular lipids to
HDL apolipoproteins. This reduces excess cholesterol
stores in cells including arterial wall macrophages [2]. In
addition to receiving cellular lipids, lipid-free apolipo-
protein A-I (apoA-I) binds to and inhibits the degrada-
tion of ABCA1, further enhancing the formation of
HDL particles [3,4]. Lipidated apoA-I on the surface of
discoidal or spherical HDL particles, however, has a
reduced affinity for ABCA1 and does not inhibit
ABCA1 degradation [3,5]. These findings suggest struc-
tural motifs present in lipid-free but not lipid-bound
apoA-I participate in ABCA1 binding and enhancement
of ABCA1 cell surface stability.
In addition to increasing ABCA1 expression transcrip-
tionally, therapies that increase ABCA1 cell surface sta-
bility represent a potential means to increase HDL
production. We previously showed that oxidation of
HDL ex vivo with peroxidase-generated tyrosyl radical
(tyrosylated HDL or tyrHDL) increases the ability of
HDL to deplete the regulatory pool of intracellular cho-
lesterol [6], increase cholesterol available for subsequent
efflux to apoA-I and other lipid acceptors [7], and
reduce the development of atherosclerosis in apoE-defi-
cient mice [8]. Enhanced depletion of intracellular cho-
lesterol was seen only when tyrHDL apoproteins and
specifically the apoAI-apoAII heterodimer in tyrHDL
were bound to the surface of spherical HDL particles,
but not in their lipid-free form. This suggests a particu-
lar conformation of tyrHDL apos when lipid-bound
mediates the enhanced effect [9]. In the current study
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cial effects by enhancing ABCA1 activity, either by
increasing ABCA1 expression or cell surface stability.
Our results indicate that, like lipid-free apoAI, tyrHDL
has no effect on ABCA1 mRNA levels, but increases
total and cell surface ABCA1, reduces calpain-depen-
dent and -independent degradation of ABCA1, and can
be crosslinked directly to ABCA1. Also like lipid-free
apoA-I but not HDL apos, apos on the surface of
tyrHDL are more susceptible to enteropeptidase diges-
tion. These results suggest that tyrosyl radical oxidation
induces changes in apolipoprotein conformation on the
surface of spherical HDL that allows lipid-bound
tyrHDL apos to interact with ABCA1 like lipid-free
apoA-I.
Methods
Materials
Cholesterol, L-tyrosine, horseradish peroxidase, hydro-
gen peroxide (30%, ACS grade), dietheylenetriaminepen-
taacetic acid (DTPA; free acid form), essentially fatty
acid-free bovine serum albumin (BSA), N-acetyl-Leu-
Leu-norleucinal (ALLN), LXR agonist T0901317 and
fetal bovine serum were purchased from Sigma. [
14C]
Oleate (55 mCi/mmol) was from GE Healthcare. Dul-
becco’s modified Eagle’s medium (DMEM) was pur-
chased from Hyclone. PE-SIL G plastic backed flexible
plates used for thin-layer chromatography analysis were
from Whatman. Nitrocellulose membranes, sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) reagents, pre-stained protein molecular mass
markers and Chelex 100 resin were from Bio-Rad. μ-
Calpain was from Calbiochem, and Trizol from Invitro-
gen. Cross-linking agent dithiobis(succinimidyl) propio-
nate (DSP) was from Pierce.
Preparation of HDL, apolipoprotein A-I, and tyrosylated
HDL
HDL3 was isolated from pooled plasma from healthy
fasting donors by density gradient ultracentrifugation
[10]. Apo A-I was purified from human plasma using
Q-Sepharose Fast Flow chromatography as previously
described [11]. Tyrosylation of HDL was carried out at
37°C for 24 h in 66 mM potassium phosphate buffer,
pH 8.0, which had been passed over Chelex 100 resin to
remove transition metal ions. The reaction mixture con-
tained a final concentration of 1 mg/mL HDL protein,
100 μM diethylenetriaminepentaacetic acid (to inhibit
metal ion-catalyzed oxidation), 100 nM horseradish per-
oxidase (250 units/mg), 100 μM H2O2, and 100 μML -
tyrosine. The reaction mixture was subjected to size
exclusion chromatography as previously described [7]
prior to use in cell culture experiments.
Cell culture
Human skin fibroblasts were cultured in DMEM supple-
mented with 10% FBS containing 50 units/ml penicillin-
streptomycin solution (Invitrogen) and grown in humi-
dified 95% air and 5% CO2 at 37°C. Confluent cells were
rinsed twice with phosphate-buffered saline (PBS) con-
taining 1 mg/ml BSA (PBS-BSA) and incubated for 24 h
in DMEM containing 2 mg/ml BSA with 30 μg/ml non-
lipoprotein cholesterol. To allow equilibration of added
cholesterol, cells were rinsed twice with PBS-BSA and
incubated for an additional 24 h in DMEM containing 1
mg/ml BSA (DMEM-BSA).
Cholesterol esterification assay
Cholesterol-loaded cells were incubated for 16 h in
DMEM-BSA and the indicated additions, washed once
with PBS, and incubated for 1 h at 37°C with DMEM
containing 9 mM [
14C] oleate bound to 3 mM BSA
[12]. Cells were chilled on ice and rinsed twice with ice-
cold PBS-BSA, twice with PBS, and stored at -20°C until
extraction. Cellular lipids were extracted with hexane:
isopropanol (3:2, v/v). Sterol species were separated by
thin layer chromatography (TLC) on PE SIL G plastic-
backed plates (Whatman) developed in hexane/diethyl
ether/acetic acid (130:40:1.5 v/v/v). Lipid spots were
identified by staining with I2 vapor and co-migration
with standard. After allowing I2 stain to evaporate, cho-
lesteryl ester spots were taken for determination of
radioactivity by liquid scintillation counting. Cell protein
was extracted by incubation of cells with 0.5 mL of 0.1
N NaOH for 1 h on a rotary shaker. Total cell protein
w a sd e t e r m i n e db yt h eL o w r ya s s a y[ 1 3 ]u s i n ga l b u m i n
as a standard.
Reverse transcriptase-PCR analysis of ABCA1 mRNA
Total RNA was isolated from cells using Trizol, follow-
ing manufacturer’s protocols. Single-strand cDNA was
synthesized by a SuperScript pre-amplification system
(Invitrogen) from 2 μgo ft h et o t a lR N A .A B C A 1D N A
amplification was performed by initial denaturation at
95°C for 3 mins. Thereafter, denaturing was at 95°C for
20 seconds, annealing at 58°C for 20 seconds, and
extension at 72°C for 40 seconds for at total of 40 cycles
(10). SYBR Green (Quanta Biosciences) was used to
detect PCR products in real-time using a Realplex
2 Mas-
tercycler thermocycler (Eppendorf). The human house-
keeping gene cyclophilin cDNA was amplified using the
same conditions. ABCA1 mRNA levels were calculated
using the comparative CT method relative to cyclophilin.
The following primers were used: human ABCA1, 5’-
GAC ATC CTG AAG CCA ATC CTG (forward), 5’-
CCT TGT GGC TGG AGT GTC AGG T (reverse);
human cyclophilin, 5’- ACC CAA AGG GAA CTG
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TGA GCT GTT TGC AG (reverse).
Gel electrophoresis and immunoblotting
Cells were scraped into N-dodecyl-b-D-maltoside–con-
taining lysis buffer (20 mM tris, 5 mM EDTA, 5 mM
EGTA, 0.5% N-dodecyl-b-D-maltoside, pH 7.5) with
complete protease inhibitor (Roche Molecular Biochem-
icals) and stored at -80°C. Cells were homogenized by
sonication, centrifuged to remove the cellular debris,
and the lysate collected for ABCA1 protein detection.
The cell lysate was run on a 5-15% gradient SDS-PAGE
gel under reducing conditions and transferred to nitro-
cellulose membrane for 16 h at 4°C. Immunoblotting
was performed using a polyclonal rabbit anti-human
ABCA1 antibody from Novus Biologicals (#NB400-105,
1:1000 dilution) and a goat anti-rabbit IgG horseradish
perodixase-conjugated secondary antibody from Sigma
(#A-0545, 1:10,000 dilution). Immunoblots were re-
probed with rabbit polyclonal anti-actin (Abcam,
#AB8227-50, 1:2000) as loading control. SDS-PAGE was
also performed for the detection of apoA-I and apoA-II
using 12% polyacrylamide gels under reducing condi-
tions followed by staining with 0.25% Coomassie Brilli-
ant Blue. Immunoblot analysis of apoA-I, HDL and
tyrHDL were performed using rabbit anti-human apoA-
I polyclonal antibody (Calbiochem #178422, 1:10,000)
and goat anti-human apoA-II monoclonal antibody (Cal-
biochem, #178464, 1:20,000).
Calpain and ALLN studies
Sensitivity of ABCA1 to digestion by exogenous calpain
following incubation with apoA-I, HDL, or tyrHDL was
performed using digitonin permeabilization and treat-
ment with 0.5 μM μcalpain for 20 min as previously
described [4]. To assess cellular levels of ABCA1 follow-
ing inhibition of endogenous calpain-dependent degra-
dation by ALLN, cells were incubated for 16 h with the
indicated conditions plus 50 μMA L L Na sp r e v i o u s l y
described [3]. Cell lysates were then analyzed by ABCA1
immunoblotting as described above.
Biotinylation of cell-surface proteins
Proteins on the surface of cells treated with the indi-
cated additions were biotinylated, harvested, and puri-
fied on streptavidin resin using a Pierce Cell Surface
Protein Isolation Kit (Pierce) following manufacturer’s
protocols [14]. Briefly, after surface biotinylation and
quenching, cells were lysed and debris was removed by
centrifugation at 10,000 × g for 10 min. Biotinylated
proteins in the supernatant (500 μl) were bound to a
streptavidin column and eluted in 250 μl of SDS sample
buffer. The total and cell surface fraction were treated
with 50 mM dithiothreitol to remove biotin, resolved by
SDS-PAGE, and immunoblotted using antibodies against
ABCA1, b-actin (Abcam), and ERK (New England
Biolabs).
Crosslinking of apoA-I, HDL or tyrHDL to ABCA1
Chemical cross-linking was performed as described by
Wang et al. [15] with minor modifications as follows. Cells
were grown to confluence in 100 mm culture dishes, cho-
lesterol loaded with non-lipoprotein cholesterol, equili-
brated, and then treated with 5 μML X RA g o n i s t
(T0901317) in DMEM-BSA for 24 h to up-regulate
ABCA1 expression. The cells were washed twice with PBS
and then treated with DMEM/BSA or the same media
containing 10 μg/mL apoA-I, HDL, or tyrHDL in DMEM-
BSA for 2 h at 37°C. Cells were then placed on ice for 15
min and washed three times with PBS. Cross linking agent
DSP was dissolved immediately before use in dimethyl
sulfoxide (Sigma) and diluted to 250 μM with PBS. 10 ml
of DSP solution was added to the cells for 1 h at room
temperature, the medium removed, and dishes were
washed twice with ice-cold PBS. Cells were lysed at 4°C in
buffer containing 20 mM Tris, 0.5 mM EDTA, 0.5 mM
EGTA, 1% Triton X-100 (BDH Chemicals, pH 7.5), with
complete protease inhibitor (Roche). by aspiration with a
fine-tipped needle, and the mixture was left to rotate at 4°
C for 30 min. Cell lysates were centrifuged at 1,500 rpm
for 10 min at 4°C to remove cellular debris The superna-
tant was collected and incubated with loading buffer in
the absence or presence of b-mercaptoethanol before load-
ing onto 4-20% gradient SDS-PAGE gels for electrophor-
esis followed by electrotransfer to a nitrocellulose sheet for
immunoblot analysis. ApoA-I cross-linked to ABCA1 was
detected by blotting the membranes with rabbit polyclonal
anti-human apoA-I antibody and goat anti-rabbit IgG
horseradish peroxidase-conjugated secondary antibody as
noted above. To detect ABCA1, the membrane was
stripped and reprobed with rabbit polyclonal antibody to
ABCA1 and goat anti-rabbit IgG horseradish peroxidase-
conjugated secondary antibody as noted above.
Enteropeptidase digestion
Lipid-free apoA-I, HDL and tyrHDL were incubated
with 0.13 U enteropeptidase (Calbiochem) per g of pro-
tein for 6 h at 37°C as previously described for apoA-I
[16]. Cleaved products were run on 12% SDS-PAGE
under reducing conditions and stained with 0.25% Coo-
massie brilliant blue. Immunoblot analysis of apoA-I
and apoA-II were performed using rabbit anti-human
apoA-I polyclonal antibod i e sa n dg o a ta n t i - h u m a n
apoA-II monoclonal antibodies.
Statistics
R e s u l t sf o rF i g u r e s1a n d2 Aw e r ea n a l y z e du s i n g
GraphPad Prism version 5.0 and are presented as the
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tal groups were determined using the Student’s t test.
Results
tyrHDL requires ABCA1 to deplete cholesterol available
for esterification
Lipid-free apoA-I depletes the regulatory pool of choles-
terol available for esterification by acyl-CoA:cholesterol
acyltransferase (ACAT) much more readily than HDL
[17], due to mobilization of this cholesterol pool by
ABCA1 and delivery to apoA-I [2]. tyrHDL mobilizes
ACAT-accessible cholesterol much more readily than
HDL, an effect that was not found to be due to direct
inhibition of ACAT or stimulation of cholesteryl ester
hydrolysis [6,7]. To investigate the role of functional
ABCA1 in this activity, HDL and tyrHDL were incu-
bated with cholesterol-loaded fibroblasts from control
a n dt w ou n r e l a t e dp a t i e n t sw ith Tangier Disease, and
the subsequent production of cholesteryl[
14C]oleate
quantified. As reported previously [6], tyrHDL showed a
markedly increased ability to deplete ACAT-accessible
cholesterol from normal fibroblasts in comparison to
control HDL (Figure 1A). tyrHDL did not have an
enhanced ability to mobilize ACAT-accessible choles-
terol compared to HDL from Tangier Disease fibro-
blasts, and depletion of this pool was reduced to similar
levels by both forms of HDL in comparison to normal
cells (Figure 1B and 1C). This suggests tyrHDL requires
ABCA1 for its enhanced cholesterol-mobilizing effect.
tyrHDL increases ABCA1 protein but not mRNA levels
To test whether tyrHDL has an effect on ABCA1 tran-
scription, cholesterol-loaded fibroblasts were incubated
with either fatty acid-free bovine serum albumin (BSA)
alone or with the addition of 10 μg/mL apoA-I, HDL, or
t y r H D Lf o r2ho r1 6hp r i o rt od e t e r m i n a t i o no f
ABCA1 mRNA level by real-time PCR. At 2 h, ABCA1
mRNA level was reduced similarly by all treatments
when compared to cholesterol-loaded cells at 0 h (Fig-
ure 2A). Following a 16 h incubation, ABCA1 mRNA
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Figure 1 tyrHDL requires ABCA1 to enhance depletion of ACAT-accessible cholesterol. Human skin fibroblasts from a normal donor and 2
unrelated Tangier Disease (TD) subjects were grown to confluence, loaded with non-lipoprotein cholesterol for 24 h, equilibrated for 24 h in
DMEM containing 1 mg/ml BSA, and then incubated in the same medium plus the indicated concentration of HDL or tyrHDL for 16 h. To
measure residual ACAT-accessible cholesterol, cells were then incubated with [
14C]oleate for 1 h, and cholesteryl [
14C]esters present in cellular
lipid extracts were determined. Results are expressed as percentage of cholesterol esterification in cells untreated with HDL or tyrHDL. Avg ± SD
of quadruplicates, representative of 3 experiments. *, p < 0.01 when compared with tyrHDL-treated cells.
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Figure 2 tyrHDL increases ABCA1 protein but not mRNA levels. Fibroblasts grown to confluence, cholesterol loaded, and equilibrated as in
Figure 1 were treated with medium containing 1 mg/ml BSA alone or plus 10 μg/ml apoA-I, HDL or tyrHDL for 2 or 16 h. (A) mRNA was
collected using Trizol™ extraction at the indicated time and qPCR was performed with cyclophilin used as the internal control. Data represent
Avg ± SD for triplicates of each sample and are representative of three experiments with similar results. *, p < 0.01 when compared with BSA-
treated cells at 16 h. (B) Cells were collected in N-dodecyl-b-D-maltoside lysis buffer with proteinase inhibitors, and ABCA1 protein was
determined following separation of proteins on 5-15% gradient gels and immunoblotting. Values at the top of lanes represent the ratio of
densitometer readings of ABCA1 protein normalized for protein disulfide isomerase (PDI) loading control, with this ratio in cholesterol-loaded
cells at 0 h set as 1. The data are representative of three experiments with similar results. Chol- indicates cells not loaded with cholesterol
loading prior to analyses.
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Page 5 of 11remained elevated in cells treated with BSA alone, but
was reduced similarly to low levels by apoAI, HDL, and
tyrHDL, consistent with depletion of cellular cholesterol
regulating ABCA1 expression by all of these treatments.
These results are consistent with previous results show-
ing no effect of apoA-I on ABCA1 mRNA level [3], and
suggest no differential effect of tyrHDL on ABCA1 tran-
scription when compared to apoA-I or HDL.
ApoA-I has previously been shown to increase ABCA1
protein levels in cultured cells and in the liver of apoA-
I-injected mice [3,4]. Consistent with these findings,
total cell homogenates obtained from cholesterol-loaded
fibroblasts incubated for 16 h with 10 μg/mL apoA-I
exhibited higher levels of ABCA1 protein than cells trea-
ted with albumin alone or similar levels of HDL (Figure
2B). Cells treated with 10 μg/mL tyrHDL showed
increased levels of ABCA1 protein when compared to
apoA-I, HDL or BSA treatments at both 2 and 16 h.
These results suggest tyrHDL has an enhanced ability to
stabilize ABCA1 protein post-translationally when com-
pared to apoA-I and control HDL.
tyrHDL protects ABCA1 from calpain-dependent and
-independent proteolysis
Calpain-dependent proteolysis of ABCA1 is mediated
through a proline, glutamic acid, serine, and threonine-
rich (PEST) sequence [4], and is inhibited by lipid-free
apoA-I but not HDL [3,4]. To determine whether
tyrHDL inhibits calpain-dependent proteolysis of
ABCA1, cholesterol-loaded fibroblasts were incubated
with BSA alone or plus apoA-I, HDL or tyrHDL for 2
or 16 h, followed by treatment with 0.5 μM μ-calpain
for 20 min [4]. ABCA1 protein degradation by μ-calpain
was observed in BSA and HDL treated fibroblasts at
both time points, with a 50-60% reduction in ABCA1
p r o t e i nw h e nc o m p a r e dt ot h ea b s e n c eo fμ-calpain
(Figure 3). No appreciable degradation of ABCA1 by
calpain was observed in apoA-I- or tyrHDL-treated cells
at either time point (Figure 3).
Lipid-free apoA-I also increases ABCA1 protein levels
by interfering with calpain-independent proteolysis of
ABCA1 [3]. Increased ABCA1 protein seen in the pre-
sence of the calpain inhibitor ALLN and BSA alone at
16 h was increased further by apoA-I, and most mark-
edly by incubation with tyrHDL (Figure 4). These results
indicate tyrHDL inhibits calpain-dependent and -inde-
pendent proteolysis of ABCA1 to a level similar or
greater than lipid-free apoA-I.
tyrHDL increases cell surface ABCA1 like lipid-free apoA-I
ApoA-I-dependent reduction of ABCA1 proteolysis
results in increased cell surface as well as total cellular
ABCA1 [18]. To determine the effect of tyrHDL on cell
surface ABCA1, cells incubated with either BSA alone
or with addition of 10 μg / m La p o A - I ,H D L ,o rt y r H D L
for 16 h were then biotinylated to label cell surface pro-
teins. Total and biotinylated cell surface ABCA1 were
isolated and probed for ABCA1, ERK (a cytoplasmic
protein), and b-actin proteins by immunoblot. Increased
cell surface ABCA1 was seen with both apoA-I and
tyrHDL treatment, paralleling the increase in total cellu-
lar ABCA1, and to a greater extent than seen with HDL
treatment (Figure 5).
tyrHDL forms crosslinks with ABCA1 similar to lipid-free
apoA-I
Several studies using the chemical cross-linker dithiobis
(succinimidyl) propionate (DSP) have suggested apoA-I
can directly bind to ABCA1, whereas HDL does not
[15,19,20]. These findings indicate conformational fea-
tures present in lipid-free but not lipid-bound apoA-I
allow the lipid-free form to bind to ABCA1. To deter-
mine whether tyrHDL might also bind to ABCA1 like
lipid-free apoA-I, cholesterol-loaded fibroblasts were
treated with LXR agonist T0901317 to upregulate cell
surface ABCA1 protein expression, and then incubated
with either BSA alone or with addition of apoA-I, HDL,
or tyrHDL for 2 h, followed by incubation with DSP for
an additional hour, and separation of whole cell homo-
genates for immunoblotting as described [15]. ApoA-I
colocalized with a band corresponding to ABCA1 under
non-reducing conditions (Figure 6). In the presence of
the reducing agent b-mercaptoethanol, free apoA-I was
observed at its expected molecular weight of 28 kDa.
Like apoA-I, when tyrHDL was DSP crosslinked, a pro-
minent anti-apoA-I antibody reactive band colocalized
with ABCA1 under non-reducing conditions, and was
released in the presence of reducing agent to a ladder of
lower molecular weight apoA-I-containing bands. In
contrast to control HDL, which showed very minimal
binding to ABCA1, these results suggest conformational
changes are present in lipid-bound tyrHDL apolipopro-
teins that allow them to bind to ABCA1 like lipid-free
apoA-I.
tyrHDL undergoes enteropeptidase digestion similar to
lipid-free apoA-I
To investigate the possibility that lipid-bound apos on
tyrHDL can assume a lipid-free conformation, the sus-
ceptibility of tyrHDL to enteropeptidase digestion was
compared to unmodified HDL and apoA-I. Enteropepti-
dase cleaves lipid-free apoA-I at Arg
188 to form a major
fragment of about 22 kDa, but has no ability to cleave
lipid bound apoA-I present either on reconstituted or
native HDL (15). Enteropeptidase treatment of lipid-free
apoA-I converted a majority of the protein to a lower
molecular weight fragment (~22 kDa), while HDL was
resistant to proteolysis (Figure 7). Exposure of tyrHDL
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Figure 3 tyrHDL protects ABCA1 from calpain-mediated degradation. Cholesterol-loaded fibroblasts pretreated with BSA plus 10 μg/ml
apoA-I, HDL, or tyrHDL for 2 h or 16 h were then incubated with or without 0.5 μM μ-calpain following digitonin permeabilization. ABCA1
protein was analyzed by 5-15% SDS-PAGE gradient gels followed by immunoblotting. Results of duplicate incubations with apoA-I, HDL, and
tyrHDL are shown. The data are representative of three experiments with similar results.
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Figure 4 tyrHDL increases cellular ABCA1 in the presence of ALLN. Cholesterol-loaded fibroblasts were incubated with BSA and 10 μg/ml
apoA-I, HDL, or tyrHDL with or without protease inhibitor ALLN (50 μM) to inhibit endogenous calpain for 16 h. ABCA1 was determined by
immunoblotting as in Figure 3. The data are representative of three experiments with similar results.
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37 kDa band consistent with an apoA-I-A-II monomer
heterodimer, both on Coomassie blue-stained SDS
PAGE gel and by immunoblotting with anti-apoAI and
anti-apoAII. This apoA-I-apoA-II heterodimer has been
identified as the protein element of tyrHDL that is
responsible for enhanced cholesterol efflux when com-
pared to HDL [9]. Nearly all of the apoA-I in this het-
erodimer on tyrHDL was digested, whereas the apoAII
component was only partially digested, possibly due to
apoAII multimers also running at this molecular weight.
The apoAI monomer band of tyrHDL was also mainly
ABCA1 
Total Cellular  Cell  Surface   
ERK 
BSA apoAI  HDL  tyrHDL  BSA  apoAI HDL  tyrHDL 
E E-Actin 
        1            1.5           0.5            2.0                 1           11.8          5.0         11.1      
Figure 5 tyrHDL increases cell surface ABCA1. Cholesterol-loaded fibroblasts were incubated with BSA alone or with 10 μg/ml apoA-I, HDL or
tyrHDL for 16 h. Total cellular ABCA1 protein was determined from whole cell lysates. Cell surface ABCA1 was determined following biotinylation
and precipitation of biotinylated cell surface proteins. Total cellular and cell surface samples were run on the same 5-15% SDS-Page gradient gel
followed by immunoblotting. Data are representative of three separate experiments with similar results.
Anti-ABCA1 Anti-apoA1 
250 KD 
25 KD 
β-ME:  -    +    -     +    -    +     -    +     -    +    -     +     -    +     -    +    
BSA   ApoAI    HDL   tyrHDL  BSA    ApoAI    HDL   tyrHDL 
Figure 6 Crosslinking of tyrHDL to ABCA1. Cholesterol-loaded fibroblasts were equilibrated in the presence of 5 μM T0901317 for 24 h to
upregulate ABCA1 expression. The cells were then treated with BSA alone or plus 10 μg/ml apoA-I, HDL and tyrHDL for 2 h, washed, and then
incubated with 250 mM of DSP for 1 h. Whole cell lysates were isolated, run on a 5-15% SDS-PAGE gradient gel and probed for the presence of
ABCA1 and apoA-I by immunoblot. 5% beta mercaptoethanol (b-ME) was used as a reducing agent to cleave crosslinks formed by DSP. Results
are representative of three separate experiments with similar results.
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Page 8 of 11digested, to fragments smaller than 22 kDa, suggesting
apoAI in tyrHDL is susceptible to enteropeptidase but
produces different fragments than native apoAI (Figure
7A and 7B). These results suggest that unlike lipid-
bound proteins on the surface of native HDL, the lipid-
bound apoAI-AII heterodimer, and also tyrosylated
a p o A I ,o nt h es u r f a c eo ft y r H D La r ea b l et oa s s u m ea t
least partial lipid-free conformations, making them sus-
ceptible to enteropeptidase digestion.
Discussion
The current study provides several lines of evidence that
oxidation of HDL by peroxidase-generated tyrosyl radical
induces conformational changes in lipid-bound HDL apo-
lipoproteins that allows them to interact with ABCA1 like
lipid-free apoA-I. Incubation of ABCA1-expressing human
fibroblasts with tyrHDL increases total cellular and cell
surface ABCA1 and inhibits calpain-dependent and -inde-
pendent proteolysis of ABCA1, as also mediated by lipid-
free apoA-I but not HDL [3,4]. Additionally, tyrHDL can
be crosslinked to ABCA1 and is susceptible to proteolysis
by enteropeptidase like lipid-free apoA-I. These findings,
therefore, represent the first demonstration of apoproteins
on the surface of spherical HDL particles behaving like
lipid-free apoAI and capable of interacting with and stabi-
lizing ABCA1 against proteolysis although lipid-bound.
The tyrHDL-induced increase in ABCA1 protein is consis-
tent with our previously observed ability of tyrHDL to
markedly deplete ACAT-accessible cholesterol [6],
increase cholesterol available for removal by apoA-I [7],
and to reduce atherosclerosis development in apoE-defi-
cient mice [8] in comparison to native HDL.
   -    +   -   +   -   +  Enteropeptidase 
37kD 
25kD 
15kD 
10kD 
 ApoAI      HDL     tyrHDL 
Anti-ApoAI Anti-ApoAII 
Enteropeptidase   -   +   -   +   -   +   -   +    -    +   -    + 
37kD 
25kD 
15kD 
10kD 
ApoAI     HDL    tyrHDL  ApoAI        HDL    tyrHDL 
A) 
B)  C) 
Figure 7 Enteropeptidase digestion of tyrHDL. Lipid-free apoA-I, HDL, and tyrHDL were treated with or without enteropeptidase 0.13 U per
μg of protein for 6 h at 37°C. Samples were run on 15% SDS-PAGE under reducing conditions and stained with Coomassie Blue (A) or
transferred to nitrocellulose for immunoblotting with anti-apoA-I (B) or anti-apoA-II (C). The data is representative of 5 separate experiments with
similar results.
Hossain et al. BMC Biochemistry 2012, 13:1
http://www.biomedcentral.com/1471-2091/13/1
Page 9 of 11Apoproteins on the surface of spherical tyrHDL increase
ABCA1 protein level and activity
Our findings indicate that tyrHDL increases cholesterol
mobilization from cells by interacting directly with
ABCA1 and enhancing ABCA1 protein stability. Like
lipid-free apoA-I, no effect was seen by tyrHDL on
ABCA1 mRNA levels. Consistent with this, previous
studies demonstrated the lipid extract of tyrHDL had no
ability to enhance cholesterol mobilization from cells
when reconstituted with control HDL apoproteins, sug-
gesting oxysterols present in tyrHDL lipids were not
driving ABCA1 expression at a transcriptional level [9].
Those studies also found the lipid-free protein fraction
of tyrHDL had a similar but slightly lower ability to
deplete ACAT-accessible cholesterol than equivalent
concentrations of lipid-free proteins from native HDL
[9]. tyrHDL proteins reconstituted into discoidal HDL
showed a modestly increased ability to deplete this cho-
lesterol pool in comparison to discoidal rHDL made
with native HDL proteins. Only when tyrHDL proteins
were reconstituted onto the surface of spherical HDL
was the full differential activity of tyrHDL compared to
native HDL observed [9]. These results suggest the
enhanced activity of tyrHDL versus native HDL is most
clearly seen when tyrHDL proteins are bound to a sphe-
rical rather than a discoidal HDL surface. They also sug-
gest that it is the particular conformation of tyrHDL
apoproteins when present on the surface of spherical
HDL, and not tyrHDL apos that dissociate off the parti-
cle surface, that are responsible for this effect.
Apoproteins on the surface of tyrHDL appear to assume a
partially lipid-free conformation
The combined results suggest HDL apoproteins oxidized
by tyrosyl radical and specifically the apoAI-AII hetero-
dimer created by this oxidation binds to the surface of
the lipoprotein differently than apoproteins on HDL,
and that the modifications induced by tyrosyl radical
oxidation produce a partially lipid-free conformation in
lipid-bound apoA-I. We propose a possible model
wherein the more lipophilic apoA-II component of the
apoAI-AII heterodimers on tyrHDL [9] tethers apoA-I
to the HDL particle surface, allowing apoA-I to be
attached to HDL while it also assumes a partially lipid-
free conformation. This conformation would facilitate
binding of the tethered apoA1 to ABCA1, and inhibition
of ABCA1 degradation. As a result, exposure of cells to
tyrHDL causes ABCA1 to be retained on the cell surface
and protected from calpain-dependent (cell surface) as
well as calpain-independent (intracellular) proteolysis.
The increased ABCA1 protein level leads to the
enhanced mobilization of excess intracellular cholesterol
that would otherwise be esterified, and makes this
cholesterol available for efflux to apoA-I and new HDL
particle generation.
The nature of the conformation of tyrHDL apoAI-AII
heterodimers on the surface of tyrHDL requires further
investigation. Particular regions of apoA-I thought to be
critical to the apoA-I-ABCA1 interaction have been sug-
gested but not yet confirmed [21-23]. The similarities in
binding to and stabilization of ABCA1 between lipid-
bound tyrHDL apos and lipid-free apoA-I suggests
tyrHDL represents a useful tool to investigate the nature
of this apoprotein-ABCA1 interaction critical to the for-
mation of new HDL particles.
Whether or not peroxidase-generated tyrosyl radical
oxidation of HDL represents a significant mechanism of
HDL oxidation in vivo is an unanswered question, and
is not the purpose of these studies. Myeloperoxidase is
known to generate tyrosyl radical as one of its oxidizing
products in addition to hypochlorous acid [24], and
LDL containing products of tyrosyl radical oxidation
have been isolated from human atherosclerotic plaques
[25]. The relative importance of tyrosyl radical oxidation
of HDL in vivo, which ex vivo appears to enhance
ABCA1 activity, as compared to other oxidative modifi-
cations of HDL and apoA-I that impair ABCA1-depen-
dent cholesterol efflux [26,27], remains to be
determined. Regardless, the ability of tyrHDL generated
ex vivo to enhance ABCA1 activity represents an impor-
tant model for the development of peptide therapies
that retain this ability when in the lipid-bound form.
Since nearly all HDL apoproteins are lipid-bound in
vivo, this signifies a major difference from apoA-I,
which only shows ABCA1-enhancing activity when
lipid-free.
Conclusions
The results presented here provide the first demonstra-
tion of lipid-bound HDL apolipoproteins capable of
enhancing ABCA1 protein level and activity like lipid-
free apoA-I, and an explanation for the previously iden-
tified salutary effects of tyrHDL.
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